Fragment-based discovery of JAK-2 inhibitors

被引：69

作者：

Antonysamy, Stephen ^{[1
]}

Hirst, Gavin ^{[1
]}

Park, Frances ^{[1
]}

Sprengeler, Paul ^{[1
]}

Stappenbeck, Frank ^{[1
]}

Steensma, Ruo ^{[1
]}

Wilson, Mark ^{[1
]}

Wong, Melissa ^{[1
]}

机构：

[1] SGX Pharmaceut Inc, Med Chem, San Diego, CA 92121 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 01期

关键词：

Fragment-based design; JAK-2; inhibitors; Structure-based design; Aminoindazole; Kinase inhibitors; MYELOPROLIFERATIVE DISORDERS; JAK/STAT PATHWAY; STATS;

D O I：

10.1016/j.bmcl.2008.08.064

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor. (C) 2008 Published by Elsevier Ltd.

引用

页码：279 / 282

页数：4

共 10 条

[1] Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis [J].

Brameld, Ken A. ;

Kuhn, Bernd ;

Reuter, Deborah C. ;

Stahl, Martin .

JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2008, 48 (01) :1-24

[2] Recent developments in fragment-based drug discovery [J].

Congreve, Miles ;

Chessari, Gianni ;

Tisi, Dominic ;

Woodhead, Andrew J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) :3661-3680

[3] Oncogenic mechanisms in myeloproliferative disorders [J].

Delhommeau, F. ;

Pisani, D. F. ;

James, C. ;

Casadevall, N. ;

Constantinescu, S. ;

Vainchenker, W. .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (24) :2939-2953

[4] Signaling through the JAK/STAT pathway, recent advances and future challenges [J].

Kisseleva, T ;

Bhattacharya, S ;

Braunstein, J ;

Schindler, CW .

GENE, 2002, 285 (1-2) :1-24

[5] JAKS AND STATS: Biological implications [J].

Leonard, WJ ;

O'Shea, JJ .

ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :293-322

[6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[7] A Src-like inactive conformation in the Abl tyrosine kinase domain [J].

Levinson, Nicholas M. ;

Kuchment, Olga ;

Shen, Kui ;

Young, Matthew A. ;

Koldobskiy, Michael ;

Karplus, Martin ;

Cole, Philip A. ;

Kuriyan, John .

PLOS BIOLOGY, 2006, 4 (05) :753-767

[8] STATs: Transcriptional control and biological impact [J].

Levy, DE ;

Darnell, JE .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (09) :651-662

[9] Cytokine signaling in 2002: New surprises in the Jak/Stat pathway [J].

O'Shea, JJ ;

Gadina, M ;

Schreiber, RD .

CELL, 2002, 109 :S121-S131

[10] JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials [J].

Pardanani, A. .

LEUKEMIA, 2008, 22 (01) :23-30

← 1 →